STERIS plc (STE) Stock Price & How to Invest

STERIS plc makes the equipment, chemistries and services that keep hospital operating rooms and medical device production sterile. Three segments carry the business. Healthcare, roughly ~70% of revenue, sells sterilizers, washers, surgical tables, endoscopy reprocessing systems and the consumables and service contracts that follow them into hospitals. Applied Sterilization Technologies (AST), close to ~20% of revenue, runs contract sterilization facilities that gamma-irradiate, e-beam or ethylene oxide treat devices for manufacturers before those devices ship. Life Sciences, near ~10%, supplies cleaning chemistries, small sterilizers and validation services to pharmaceutical producers. Legally the parent is an Irish plc, operationally the company runs out of Mentor, Ohio, and the ordinary shares trade on the NYSE inside the S&P 500. Headcount is roughly ~17,900.

The investment picture rests on installed base rather than on new orders. A sterilizer sold today drags decades of chemistries, filters, service visits and replacement parts behind it, which is why STERIS grew revenue ~9% in fiscal 2026 to ~$5.9 billion and guided fiscal 2027 to another ~7% to ~8% with adjusted EPS of ~$11.10 to ~$11.30. Capital equipment is the cyclical part and moves with hospital budgets; AST moves with how many devices its customers actually manufacture, so a destocking cycle at a large device maker shows up in STERIS volumes with a lag. Cash generation is the quiet strength, with fiscal 2027 free cash flow guided near ~$800 million against gross debt of roughly ~$1.9 billion, or about ~1.1x EBITDA, leaving room for the ~$600 million chemistries plant announced in North Carolina, a fresh ~$1 billion buyback authorization and a dividend raised for a 21st consecutive year.

Ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. Subsidiary Isomedix agreed to costs of up to roughly ~$48 million to resolve personal injury claims tied to an Illinois sterilization plant, and EtO emissions rules adopted by the EPA in 2024 remain in flux under reconsideration, which cuts both ways: looser rules reduce compliance capex, while continued legal uncertainty has already caused the company to hold off on some capacity expansion. Hospital capital spending is the second pressure point, since sterilizers and surgical tables are deferrable purchases when health systems face margin strain. AST volumes depend on customer manufacturing schedules rather than on STERIS decisions, so device industry destocking passes straight through. Tariffs and currency both moved reported results in fiscal 2026 and management flagged them again in the fiscal 2027 outlook. Valuation is itself a risk, because a high-twenties trailing multiple leaves little room for a guidance cut.

8 analysts publish price targets on STE, averaging $263.12 against a $239.15 price as of August 2026, or +10.0%. The published targets run from $232.00 to $280.00, a narrow spread, and the ratings split 6 buy, 3 hold, 0 sell. Over the last six months there has been 1 raise and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full STE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on STERIS plc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Recurring consumables and service, not equipment sales. Most of what STERIS books each quarter is not a machine. The most optimistic published target, $280.00, assumes this works close to its best case.

The case against. Ethylene oxide is the exposure that separates STERIS from an ordinary medical equipment name. The most pessimistic target, $232.00, is roughly what STE is worth if this bites instead.

Read the full bull and bear case on STE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see STERIS plc's investor relations page or your broker.

• Revenue (TTM): ~$6.04 billion
• Market cap: ~$23.2 billion at a share price near ~$239
• Trailing P/E: ~29x on trailing EPS of ~$8.18
• Forward P/E: ~21x on fiscal 2027 adjusted EPS guidance of ~$11.10 to ~$11.30
• Dividend: ~$2.76 per share annualized, a yield near ~1.2%, raised for a 21st straight year
• Leverage: ~$1.9 billion gross debt, roughly ~1.1x EBITDA

STERIS runs a March fiscal year, so the trailing twelve months as of August 2026 spans the final three quarters of fiscal 2026 plus the June 2026 quarter that opened fiscal 2027. Fiscal 2027 first quarter revenue rose ~7% to ~$1.5 billion with adjusted EPS of ~$2.59, and full-year guidance of ~7% to ~8% reported growth was reiterated. The gap between the ~29x trailing and ~21x forward multiple reflects both expected earnings growth of ~9% to ~11% and the sizeable adjustments, including amortization and restructuring, that separate GAAP EPS from the adjusted figure guidance is built on.

Other names that sit close to STE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get STE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so STE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where STE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

STE is a slow-and-steady infection prevention compounder whose recurring revenue and ~1.1x leverage are the attraction, and whose ethylene oxide exposure and premium multiple are the price of admission.

Whether STE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is STE a buy or a sell?, and where the stock could go from here in the STE stock forecast.

For income investors, whether STE pays a dividend and how the payout looks is covered in does STE pay a dividend? And to weigh STE against a peer, read the full side-by-side comparisons: STE vs SHC and STE vs AB.